Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by CanadaCoinon Nov 02, 2019 2:28pm

126 Views

Post# 30301213

RE:RE:RE:RE:RE:I emailed IR to ask about timelines

That's quite the mouthful you posted Mary.

And with that logic, the investing public should never assume that phase 2B will ever be completed. :-)

Right now, the target is still Q4. You will have to find a way to live with it Mary. May I suggest prayer.

HailMary wrote: What it does is further validate my point, that the study is further delayed

The company's orginal promise in March:

" The study is being conducted by Veristat, Inc. (“Veristat”) in approximately 35 clinical sites across Canada and is expected to have a top-line data read-out this summer.  "

So they missed that one, but it was "only expected", right? They made it okay with this:

" Previous guidance for enrollment of the last patient had been late calendar Q3 2019, but this will now occur in calendar Q4 2019. The delay is largely the result of the rigorous screening discipline and a temporary slowdown in patient recruitment due to the summer holiday period. "

Okay, so summer holidays have been over for two months but still not filled?? Hmmm, I guess just because they broke their first promise of summer, there's no way they break this second promise of Q4 is there??

Oh wait, I guess they can because they're not actually going to be responsible. They already shuffled the blame to Veristat, stating that it's outside Antibes control. Maybe ask IR about that fact next time you chat with them .... Mary

CanadaCoin wrote: "It's facts guys, the study is not near complete and won't be complete for some time. They've had seven months and it's only ~2/3rds full at last count"

Glad to see you have finally figured out how to use the 'quote' feature Mary. :) It truly helps me to point out that 435cliff contacted the company [see below] and the response from them was that the patient enrollment is still slated to be completed this quarter, as per their last guidance in the Aug 27th press release! And please understand that I have the right to either accept this management quote as being legit.....or contact the company and ask them to verify. I chose to trust this posted information.

You are the other hand, refuse to comprehend the english language. And refuse to disclose where you get your contrary data.

I don't even have the opportunity to verify what you post...because of your refusal. And you have the audacity to think that we need to accept the data of an anonymous poster at face value.....or face your ridicule. Really? :-)

Miss Mary, you are indeed the poster to be wary of.